rare diseasesFrench biopharma duo THX Pharma and Biocodex strike rare diseases licensing deal worth up to €173MFrench biopharma THX Pharma has signed a strategic licensing deal with Biocodex, an independent French pharmaceutical group, to advance two drug candidates in three rare genetic disorders with high unmet … more ➔
Microbioticaclinical dataMicrobiotica’s microbiome therapy showed 63% remission in ulcerative colitis phase 1b trialCambridge-based Microbiotica’s ulcerative colitis (UC) candidate met its primary and secondary phase 1b study objectives on safety, efficacy signals and bacterial engraftment. The company has reported … more ➔
Araris Biotech AGAntibody drug conjugatesSwiss-Japanese ADC player Araris expands Chugai pact with $780m licensing agreementZurich-based oncology biotech Araris Biotech AG has entered into a research collaboration with an option to license with Japan’s Chugai Pharmaceutical, a subsidiary of Roche. The aim of the partnership … more ➔
Freepik.comAntibodyThis Memo sticks: CSL bites in Switzerland for antibody collaborationThe Australian–Swiss plasma specialist CSL is relying on technology from Switzerland for recombinant polyclonal immunoglobulins (IgG). With Memo Therapeutics, the company has entered into a collaboration … more ➔
financing4Moving Biotech raises €12m to prove whether GLP-1 can crack osteoarthritisAfter more than a decade of failed drug development efforts, osteoarthritis remains one of biopharma’s most stubborn challenges. Despite affecting more than 600 million people worldwide, no therapy … more ➔
© Bayer LeverkusenStrokeBayer: At last, success with coagulation factor XIa in phase 3 stroke trialBayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class … more ➔
FundraisingDublin-based Aerska secures $39M Series A to push RNA medicines into the brainAerska, a biotechnology company focused on RNA medicines for brain diseases, has raised €32 million in a Series A financing to advance its lead technology toward clinical development. The round was … more ➔
Real estateU.K. life sciences infrastructure gets a boost as London and Cambridge expandTwo of the U.K.’s largest life sciences real-estate projects have moved forward within days of each other, with major expansion plans unveiled in London and Cambridge as both regions look to add new … more ➔
RoyaltiesBioArctic is cashing in on Eisai and Biogen growing sales in Alzheimer’s diseaseStockholm-based BioArctic is receiving SEK 127 million (about €11.9 million at today’s exchange rate) in royalties from the Alzheimer’s disease therapy Leqembi (lecanemab). more ➔
IPOAgomab goes public on Nasdaq as biotech IPOs top $1bn in a single weekJust three weeks after announcing its plans for a U.S. listing, Belgium-based Agomab has gone public on Nasdaq after pricing its IPO at $16 per share, aiming to bring in about $200 million in gross proceeds … more ➔
Microbiotica
Araris Biotech AG
Freepik.com
© Bayer Leverkusen
